GlassScriptPhysician profile
Sheila Patterson
NPI 1700267259
$7,703.42
in general payments reported to CMS, 2019-2025
26 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $1,266 · 2023: $1,615 · 2024: $2,229 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,926 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,925.83 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,392.81 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,010.31 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $874.65 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $638.79 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $480.10 | 2024-2025 | Epclusa, Livdelzi |
| Regeneron Healthcare Solutions, INC. | $277.09 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $235.14 | 2021-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $215.96 | 2024-2025 | Vowst, Zenpep |
| Phathom Pharmaceuticals, INC. | $189.13 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $178.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $176.29 | 2021-2024 | Dificid |
| Daiichi Sankyo INC. | $156.63 | 2022-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $131.49 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $120.49 | 2022-2023 | Ocaliva |
| Ardelyx, INC. | $106.89 | 2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $89.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $73.30 | 2022 | |
| Medtronic, INC. | $69.71 | 2024 | Bravo |
| Pfizer INC. | $59.38 | 2021-2022 | |
| Ethicon US, LLC | $57.88 | 2022 | |
| Ferring Pharmaceuticals INC. | $50.86 | 2022-2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.21 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $32.96 | 2023 | |
| Organon LLC | $18.33 | 2023 | Renflexis, Hadlima |
| Celgene Corporation | $17.18 | 2024 | Zeposia |
| Sandoz INC. | $13.66 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.